# Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients

> **NCT03422029** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 20 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 177Lu-Dotatate PRRT

## Key facts

- **NCT ID:** NCT03422029
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-31
- **Primary completion:** 2020-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03422029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03422029, "Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03422029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*